SynthesisWorld journal of surgical oncology2025
Prognostic value of platelet to lymphocyte ratio in patients with cervical cancer: an updated systematic review and meta-analysis.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Exploratory Analysis of Systemic Inflammatory Indices Across Locoregional Tumor Progression Parameters in Cervical Cancer: The CERTIFIKO Prospective Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Article
- [Interpretable machine learning models for preoperative precision prediction of perineural invasion in cervical cancer to support treatment decision: a multicenter retrospective study].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- LncRNA CXCL8-203 down-regulates IL-8 and enhance the radiosensitivity of Siha cells in cervical cancer.Scientific reports · 2026Article
- Prognostic Survival Model Following Primary Radical Surgery for Early-Stage Cervical Cancer.Cancers · 2026Article
- Prognostic value of the lactate dehydrogenase-to-albumin ratio (LAR) combined with clinicopathological indicators for predicting outcomes in locally advanced cervical cancer undergoing concurrent chemoradiotherapy: a retrospective cohort study and nomogram development.American journal of cancer research · 2026Article
- Baseline platelet-to-lymphocyte ratio is associated with severe immune effector cell-associated toxicities in diffuse large B-cell lymphoma patients receiving anti-CD19 CAR T-cell therapy.Frontiers in immunology · 2026Article
- Pretreatment CRP-Albumin-Lymphocyte (CALLY) Index as a Prognostic Biomarker of Survival and Recurrence-Free Survival in Patients With Early-Stage Cervical Cancer After Radical Hysterectomy: A Multicenter Retrospective Cohort Study.Obstetrics and gynecology international · 2026Article
- Pretreatment prognostic nutritional index and immune status for response to preoperative neoadjuvant chemotherapy in cervical squamous cell carcinoma: an exploratory retrospective study.Frontiers in oncology · 2026Article
- Site-Specific Inflammatory Signatures in Metastatic NSCLC: Insights from Routine Blood Count Parameters.Medicina (Kaunas, Lithuania) · 2025Article
- Pan-immune-inflammation value as an independent prognostic marker in patients with brain metastases.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe identification of biomarkers that reliably forecast cervical cancer (CC) outcomes is a key area of research. Several studies have explored the link between the platelet-to-lymphocyte ratio (PLR) and cervical cancer prognosis, though the results are not entirely conclusive.
methodsPubMed, Embase, Web of Science, and the Cochrane Library were used to search, with studies published up to May 30, 2024. The selection of studies followed predetermined inclusion and exclusion criteria. Overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) were primary outcomes. Hazard ratios (HR) and 95% confidence intervals (CIs) were calculated. Sensitivity and subgroup analyses were performed to evaluate the stability and investigate potential heterogeneity. Review Manager version 5.4.1 and STATA version 15.0 were conducted to analyze.
resultsThirty cohort studies, involving 8,597 patients, were included. The pooled data showed that a higher PLR was associated with worse OS significantly (HR = 1.77, 95% CI: 1.43-2.19; p < 0.0001), PFS (HR = 1.69, 95% CI: 1.26-2.27; p = 0.0004), and DFS (HR = 1.57, 95% CI: 1.12-2.18; p = 0.008). Subgroup analysis indicated that the prognostic relevance of PLR was most prominent in patients who underwent both surgery and radiotherapy, as well as those from Asia and the America. Furthermore, a PLR threshold above 150 was associated with improved predictive accuracy.
conclusionIncreased PLR among cervical cancer patients was significantly correlated with reduced OS, PFS, and DFS, pointing to its potential role as an independent prognostic marker. Nonetheless, additional prospective research is required to verify this finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.